| 2.9 0.02 (0.69%) | 01-09 13:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.75 | 1-year : | 4.08 |
| Resists | First : | 3.21 | Second : | 3.49 |
| Pivot price | 2.94  |
|||
| Supports | First : | 2.75 | Second : | 2.28 |
| MAs | MA(5) : | 2.85 |
MA(20) : | 2.96 |
| MA(100) : | 7.71 |
MA(250) : | 8.29 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 28.1 |
D(3) : | 17.2 |
| RSI | RSI(14): 33.2 |
|||
| 52-week | High : | 13.13 | Low : | 2.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TPST ] has closed above bottom band by 48.7%. Bollinger Bands are 86.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.03 - 3.05 | 3.05 - 3.06 |
| Low: | 2.78 - 2.79 | 2.79 - 2.81 |
| Close: | 2.86 - 2.88 | 2.88 - 2.9 |
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Tue, 25 Nov 2025
Tempest Therapeutics stock falls after $4.25 million direct offering - MSN
Tue, 25 Nov 2025
Tempest Announces Up To $8.35 Million Registered Direct - GlobeNewswire
Tue, 25 Nov 2025
Tempest Therapeutics raises $4.25 million in registered direct offering - Investing.com
Wed, 19 Nov 2025
Tempest Therapeutics Announces New Leadership and Acquisition - TipRanks
Wed, 19 Nov 2025
Tempest gains CAR Ts for 65% of the company; stock drops - BioWorld MedTech
Wed, 19 Nov 2025
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 11.8 (%) |
| Shares Short | 250 (K) |
| Shares Short P.Month | 154 (K) |
| EPS | -9.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -89.4 % |
| Return on Equity (ttm) | -405.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.31 |
| PEG Ratio | 0 |
| Price to Book value | 2.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|